EORTC Abstracts at ASCO 2014 in Chicago

The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May – 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.

Oral Abstract Sessions

Abstract # 4500
Monday, 02 June, 9:45 – 9:57, E Hall D1

Cora N. Sternberg, Iwona Skoneczna, J.M.Kerst, Sophie Fossa, Peter Albers, Mads Agerbaek, Herlinde Dumez, Maria De Santis, Christine Theodore, Michael Leahy, J.D. Chester, Antony Verbaeys, Armelle Caty, Gedske Daugaard, Sandrine Marreaud, Samantha Cambier, Richard Sylvester
Final Results of EORTC Intergroup Randomized Phase III Trial Comparing Immediate versus Deferred Chemotherapy after Radical Cystectomy in patients with pT3T4 and/or N+ M0 Transitional Cell Carcinoma of the Bladder.

Abstract #LBA9008
Monday, 02 June, 17:12 – 17:24, E Arie Crown Theater

Alexander M. Eggermont, Vanna Chiarion-Sileni, Jean Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo Antonio Ascierto, Jon M. Richards, Celeste Lebbe, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Ravichandra Karra Gurunath, Veerle de Pril, Stefan Suciu, Alessandro Testori
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

Abstract #3501
Monday, 02 June, 8:12 – 8:24, E Arie Crown Theater

Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, Jozef Janssens, Baruch Brenner, Peter Schmidt, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian W.B. Fauth, Carla Hannig, John Raymond Zalcberg, Niall C. Tebbutt, Murielle E. Mauer, Carlo G. M. Messina, Manfred P. Lutz, Eric Van Cutsem
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Disease free survival results at interim analysis.

Abstract #2003
Sunday, 01 June, 9:12 9:24, E450

Wolfgang Wick, Thierry Gorlia, Martin J. Van Den Bent, Charles J Vecht, Jonathan Steuve, Alba Ariela Brandes, Michael Platten, Markus A Kosch, Monika E. Hegi, Benoit Lhermitte, Vassilis Golfinopoulos, Mario Campone, Jean-Sebastien Frenel, Martin J.B. Taphoorn, Gianfranco A. Pesce, Patrick Roth
Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779)versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.

Poster Highlights Session

Abstract #2034
Friday, 30 May, 13:00 – 16:00, E354b, Poster Board #25

Divine Ewane Ediebah, Francisca Galindo-Garre, Bernard M.J. Uitdehaag, Jolie Ringash, Jaap C. Reijneveld, Linda Dirven, Efstathios Zikos, Corneel Coens, Martin J. Van Den Bent, Andrew Bottomley, Martin J.B. Taphoorn
Joint modeling of longitudinal health-related quality of life (HRQoL) data and survival.



General Poster Sessions

Abstract # 9067
Saturday, 31 May, 8:00 – 11:45. S Hall A2, poster board #271

Stefan Suciu, Natalie Ives, Alexander M. Eggermont, John M. Kirkwood, Paul Lorigan, Svetomir Markovic, Claus Garbe, Keith Wheatley
Predictive importance of ulceration on the efficacy of adjuvant interferon-a: An individual patient data meta-analysis of 15 randomized trials in > 7500 melanoma patients.


Abstract #10579
Monday, 02 June, 8:00 – 11:45, S Hall A2, Poster Board #287

Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, Sant P. Chawla, Thierry Gil, Sophie Piperno-Neumann, Sandrine Marreaud, Rachel Hodge, Winette T.A. Van Der Graaf
Pazopanib in uterine sarcoma: Review of two EORTC & GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma.


Abstract #9570
Sunday, 01 June, 8:00 – 11:45. S Hall A2, Poster Board #220

Efstathios Zikos, Corneel Coens, Miriam Sprangers, Eva Greimel, Irina Ghislain, Divine Ewane Ediebah, Henning Flechtner, Andrew Bottomley
Has health-related quality of life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials.


Abstract #TPS659
Monday, 02 June, 8:00 – 11:45, S Hall A2, Poster Board #119B

Tryfonidis K., Bogaerts J., Martell R., Sledge G., Balmana J., Audeh W., Deleersnijder A., Favorito F., Agarwal S., Rizzetto G., Messina C., Slaets L., Goulioti T., Tutt A., Cameron D., Turner N.

A phase III randomized trial of niraparib versus physician’s choice in previously- treated, HER2 negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.


For more information concerning EORTC cancer clinical research, please contact: www.eortc.org/contact

John Bean, PhD

EORTC, Medical Science Writer

Back to news list